Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...
Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...
Zacks.com on MSN5d
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...
Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,030.00. The ...
Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...
© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...
Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...
Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback